Introduction

Demand for prescription weight-loss medicines has increased in recent years, placing Novo Nordisk and Eli Lilly at the centre of one of the pharmaceutical industry’s biggest commercial rivalries. As the manufacturers of Wegovy and Zepbound, the two companies are investing heavily in marketing to strengthen their position in a rapidly expanding market. While these medicines have transformed obesity treatment for many patients, their promotion has sparked debate over whether prescription drugs should be advertised in a way that resembles consumer products and whether current advertising rules are keeping pace.

Why Novo Nordisk and Eli Lilly Are Competing So Aggressively

The intense competition between Novo Nordisk and Eli Lilly is driven by the extraordinary commercial potential of the obesity treatment market. With obesity rates continuing to rise worldwide, demand for effective prescription weight-loss medicines has grown rapidly. Marketing plays an important role in educating patients about obesity as a chronic medical condition. Many individuals remain unaware that prescription medicines are available as part of obesity management, and pharmaceutical companies argue that greater awareness encourages patients to seek medical advice. 

The Legal Framework

The UK’s regulatory framework places clear limits on the advertising of prescription medicines. The Human Medicines Regulations 2012 and the CAP Code prohibit businesses from promoting prescription-only medicines directly to consumers or encouraging members of the public to request them. Consequently, companies operating in the market must carefully structure their advertising and promotional activities to remain within the law. Similarly, the European Union prohibits direct-to-consumer advertising of prescription-only medicines under Article 88 of Directive 2001/83/EC, reflecting the same principle that prescribing decisions should be based on medical rather than commercial considerations.

The United States, on the other hand, permits direct-to-consumer advertising of prescription medicines. This allows pharmaceutical companies to advertise prescription weight-loss drugs, including Wegovy and Zepbound, provided their advertisements comply with the U.S. Food and Drug Administration’s (FDA) requirements, including presenting a fair balance between the benefits and risks of the medicine.

Impact on Law Firms

The continued expansion of the weight-loss drug market is likely to increase demand for legal advice across several practice areas.

  • Commercial and Contracts lawyers negotiate agreements with advertising agencies, digital platforms and marketing partners. 
  • Competition lawyers advise on market practices as rivalry between manufacturers intensifies. 
  • Intellectual Property teams also play a key role in protecting patents, trade marks and branding associated with high-value pharmaceutical products.

Do Regulators Need to Step In?

Although the UK prohibits the direct advertising of prescription-only medicines, pharmaceutical companies can still raise awareness of obesity through educational campaigns and partnerships with healthcare providers. On social media, however, influencer endorsements and sponsored content can blur the line between education and promotion. Any reforms will need to balance between protecting public health and allowing companies to communicate legitimate medical information.

Conclusion

The growing popularity of weight-loss medications is unlikely to slow. The challenge will be finding the right balance between supporting innovation and protecting consumers from misleading or overly persuasive promotion. Whatever approach is adopted, the regulation of prescription medicine advertising will remain a key issue as the pharmaceutical industry adapts to one of its fastest-growing markets.